DOT1L705
DOT1L705 is a PROTAC degrader that targets DOT1L. DOT1L705 recruits the VHL E3 ubiquitin ligase to induce proteasomal degradation of DOT1L. DOT1L705 reduces the viability of leukemia cells. DOT1L705 inhibits H3K79 methylation. DOT1L705 can be used in studies related to MLL-rearranged leukemia.
(Pink: DOT1L ligand (HY-135127); Blue: VHL E3 ligase ligand; Black: linker).
For research use only. We do not sell to patients.
- CAS No.: 3050756-34-5
- Formula: C61H72ClF3N12O13S2
- Molecular Weight:1337.88
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
DOT1L705 (0.026-1 μM) inhibits H3K79 methylation, reduces viability of MLL-rearranged acute myeloid leukemia cell lines.
DOT1L808 (5-46.6 nM) inhibits H3K79 methylation, reduces viability of MLL-rearranged acute myeloid leukemia cell lines.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MV-4-11
-
Concentration:0-10 μM
-
Incubation Time:6 h-96 h
-
Result:Induced dose-dependent degradation of DOT1L in MV-4-11 cells with a DC50 of 0.33 μM, achieving near-complete degradation within 4-6 hours (sustained for 96 hours).
Reduced H3K79me2 levels in MV-4-11 cells with an IC50 of 0.026 μM, 13-fold more potent than its effect on DOT1L protein levels.
-
Cell Line:MLL-rearranged cell lines
-
Concentration:0.01-100 μM
-
Incubation Time:5 days
-
Result:Selectively inhibited viability of MLL-rearranged cell lines (MV-4-11 IC50 = 0.29 μM; EOL-1 IC50 = 0.39 μM; Pfeiffer IC50 = 0.80 μM) while showing minimal activity against non-MLL-rearranged lines (KG-1 IC50 > 50 μM).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57 BL/6 female mice ( 7−8 week old)[1]
-
Dosage:1 mg/kg (pharmacokinetics); 10 mg/kg (in vivo efficacy)
-
Administration:in vitro; i.p. (single dose, pharmacokinetics); i.p. (BID, in vivo efficacy)
-
Result:
Reduced tumor volumes by >50% relative to vehicle control in an MV-4-11 subcutaneous xenograft model at 10 mg/kg BID i.p., with no significant body weight loss.
Showed reduced H3K79me2 levels in tumor lysates from the MV-4-11 subcutaneous xenograft model, confirming on-target activity.
Chemical Information
-
CAS No. 3050756-34-5
-
Molecular Weight 1337.88
-
Formula C61H72ClF3N12O13S2
-
SMILES
ClC1=C(N=CC=C1)[C@H](C2=C3OC(F)(OC3=CC=C2)F)NC4=C(C=C(C=C4)S(C)(=O)=O)NC5=NC(N6CCNCC6)=NC(OCCOCCOCCOCCOC7=CC(C8=C(N=CS8)C)=CC=C7CNC([C@@H]9C[C@H](CN9C([C@@H](NC(C%10(CC%10)F)=O)C(C)(C)C)=O)O)=O)=N5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DOT1L705 Related Classifications
Cat. No.: HY-181787
Powered by Bioz
- DOT1L705
- 3050756-34-5
- PROTACs
- Histone Methyltransferase
- H3K79 methylation
- orthotopic models
- VHL E3 ubiquitin ligase
- MLL-rearranged acute myeloid leukemia cell lines
- DOT1L
- proteasomal degradation
- MV-4-11 xenograft model
- MLL-rearranged leukemia cells
- menin inhibitor-resistant leukemia cells
- Inhibitor
- inhibitor
- inhibit